BB BIOTECH news, videos and press releases
For more news please use our advanced search feature.
BB BIOTECH - More news...
BB BIOTECH - More news...
- EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share
- EQS-Adhoc: BB Biotech AG publishes its 2024 annual report
- EQS-News: Annual Report 2024: BB Biotech positions for structural sector recovery amid shifting market dynamics
- EQS-News: BB Biotech: Preliminary full-year 2024 results and dividend proposal
- EQS-Adhoc: BB Biotech AG closes the 2024 fiscal year with a profit
- Edison issues report on BB Biotech (BION)
-
BB Biotech – equity proposition
- EQS-Adhoc: BB Biotech AG publishes its interim report
- EQS-News: BB Biotech: Strategic reallocation of portfolio assets progressing
- Edison issues report on BB Biotech (BION)
-
BB Biotech – executive interview (14 October 2024)
- EQS-Adhoc: BB Biotech AG publishes its interim report and announces a new head of its investment management team
- EQS-News: Substantial pipeline progress at several portfolio companies offsets rate-related market volatility
- Edison issues report on BB Biotech (BION)
- Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis
- EQS-Adhoc: BB Biotech AG publishes its interim report
- EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
- EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
- EQS-Adhoc: BB Biotech AG publishes its 2023 annual report
- EQS-News: Investor interest returns – dividend yield remains high for 2024
- EQS-Adhoc: BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
- EQS-News: BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle
- EQS-Adhoc: BB Biotech AG publishes its interim report
- EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
- EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
- EQS-Adhoc: BB Biotech AG publishes its interim report
- EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms
- EQS-Adhoc: BB Biotech AG publishes its interim report
- EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks
- EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
